RESUMEN

OBJECTIVES: Chronic diarrhoea and severe wasting associated with HIV infection were first described in East African patients as slim disease (SD) in 1985. The main histological features are flattening of the villi (villous atrophy) and crypt hyperplasia (elongated crypts), i.e., HIV enteropathy (HIVE). Selective loss of mucosal clusters of differentiation 4 (CD4)+ T helper (Th)17+ lymphocytes is the immunological hallmark of HIVE. This review explores (i) the historical background of HIVE and SD, (ii) the relationship between gut mucosal CD4+ Th17+ and intestinal-resident intra-epithelial gamma delta (IRIE) T lymphocytes in pathogenesis of HIVE, (iii) the role of cytokines in regulation of intestinal epithelial proliferation, and (iv) the role of antiretroviral therapy in HIVE. METHODS: Recent studies have highlighted the role of IRIE T lymphocytes, mostly CD8+, in regulating gut epithelial regeneration. CD4+Th17+ and IRIE T cells are necessary to maintain intestinal barrier integrity and mucosal antimicrobial immune defence. However, the immunological cross-talk between such lymphocyte sub-sets culminating in HIVE is uncertain. We undertook a narrative literature review under the headings 'HIVE', 'SD', and 'Highly active antiretroviral therapy (HAART). Relevant studies were located using the electronic search engines Google Scholar and PubMed from 1984 to 2022. RESULTS: Depletion of Th17+ cells in the lamina propria, attributed to low-level viraemia, is accompanied by concomitant increase in the density of gut mucosal IRIE T lymphocytes in AIDS. The latter express a broad range of cytokines (interferon-gamma, tumor necrosis factor-alpha, interleukin-17) and chemokines e.g., keratinocyte growth factor, post exposure to HIV-infected cells. Keratinocyte growth factor induces epithelial proliferation mainly in the crypts, leading to functional immaturity of enterocytes, reduced gut absorptive surface area and malabsorption in animal experiments. Of note, the absence of IRIE T cells is associated with a reduction in epithelial cell turnover. Patients with HIVE receiving early HAART show enhanced expression of mucosal repair genes and improvement of gut symptoms. CONCLUSION: Multiple lines of enquiry suggest HIVE is directly related to HIV infection and is a consequence of perturbations in mucosal CD4+Th17+ and IRIE T lymphocytes. The pathological result is enterocyte immaturity and dysfunction. SD whose main features are malabsorption, diarrhoea and weight loss, is a severe clinical expression of HIVE. A better understanding of immuno-pathogenesis of HIVE opens a window of opportunity for the potential use of immunotherapy in HIV disease and other T cell-mediated enteropathies.

Asunto(s)

Enteropatía por VIH , Infecciones por VIH , Síndrome de Emaciación por VIH , Animales , Humanos , Síndrome de Emaciación por VIH/patología , Factor 7 de Crecimiento de Fibroblastos/uso terapéutico , Enteropatía por VIH/patología , Mucosa Intestinal/patología , Diarrea , Linfocitos T CD4-Positivos

RESUMEN

BACKGROUND: Infectious diarrhea is a common problem in the developing world, especially among people living with HIV/AIDS. Traditional diagnostic methods such as stool culture and microscopic examination are limited by resources and poor sensitivity. The use of molecular diagnostics for enteropathogen detection in this region of sub-Saharan Africa has not been fully explored. We sought to identify risk factors and characterize enteropathogens from diarrheic stools of HIV-positive patients in Gondar, Ethiopia using multiplex molecular panels targeting key infectious agents. METHODS: A cross-sectional study of 100 stool samples was performed. Samples were collected consecutively from HIV- positive patients presenting with diarrhea at University of Gondar Hospital clinic, a major center in NW Ethiopia. Genomic DNA was extracted from stool and processed using a multiplex molecular panel Allplex™ [Seegene, Canada]. Correlations between patient characteristics, symptoms, public health risk factors, and enteropathogen type (s) were studied. Eighty-six samples were successfully analyzed by molecular methods. RESULTS: The mean age was 35 with 43% male. Eighty percent lived in an urban area, 18% had access to well water only, and 81% practiced proper hand hygiene. The majority of patients (72%) were receiving HAART with a median CD4 cell count of 362/µL. Multiple pathogens were detected in 94% of specimens, with an average of 5 enteropathogens per sample. Common bacteria, viruses, and parasites detected were Shigella spp./enteroinvasive E. coli (80%), enterotoxigenic E. coli (73%), Norovirus (16%) and B. hominis (62%). CD4 cell count < 500/ µL was associated with the presence of viruses (p = 0.004) and the absence of STEC (p = 0.010). The use of HAART or CD4 levels was not associated with the number of enteropathogens detected. CONCLUSIONS: Diarrheic stool from HIV-positive outpatients in Gondar, Ethiopia had on average 5 enteropathogens present in their stool. Shigellaspp./enteroinvasive E. coli and enterotoxigenic E. coli are the major pathogens, not dissimilar to immunocompetent individuals in low income countries.

Asunto(s)

Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Diarrea/diagnóstico , Heces , Seropositividad para VIH/complicaciones , Técnicas de Diagnóstico Molecular/métodos , Infecciones Oportunistas Relacionadas con el SIDA/microbiología , Infecciones Oportunistas Relacionadas con el SIDA/parasitología , Infecciones Oportunistas Relacionadas con el SIDA/virología , Adolescente , Adulto , Terapia Antirretroviral Altamente Activa/efectos adversos , Bacterias/clasificación , Bacterias/genética , Bacterias/aislamiento & purificación , Recuento de Linfocito CD4 , Niño , Estudios Transversales , Pruebas Diagnósticas de Rutina/métodos , Diarrea/microbiología , Diarrea/parasitología , Diarrea/virología , Escherichia coli/genética , Escherichia coli/aislamiento & purificación , Etiopía , Heces/microbiología , Heces/parasitología , Heces/virología , Femenino , VIH , Enteropatía por VIH/diagnóstico , Enteropatía por VIH/microbiología , Enteropatía por VIH/parasitología , Enteropatía por VIH/virología , Seropositividad para VIH/microbiología , Seropositividad para VIH/parasitología , Seropositividad para VIH/virología , Humanos , Masculino , Persona de Mediana Edad , Norovirus/genética , Norovirus/aislamiento & purificación , Factores de Riesgo , Shigella/genética , Shigella/aislamiento & purificación , Adulto Joven

RESUMEN

Persons with human immunodeficiency virus (HIV) infection often develop complications related directly to the infection, as well as to treatment. Aging, lifestyle factors, and comorbidities increase the risk of developing chronic conditions such as diabetes mellitus and chronic kidney disease. HIV-associated neurologic complications encompass a wide spectrum of pathophysiology and symptomatology. Cardiovascular and pulmonary conditions are common among persons with HIV infection. Although some specific antiretroviral medications have been linked to disease development, traditional risk factors (e.g., smoking) have major roles. Prevention and management of viral hepatitis coinfection are important to reduce morbidity and mortality, and new anti-hepatitis C agents produce high rates of sustained virologic response. Antiretroviral-associated metabolic complications include dyslipidemia, hyperglycemia, and loss of bone mineral density. Newer options generally pose less risk of significant systemic toxicity and are better tolerated. Family physicians who care for patients with HIV infection have a key role in identifying and managing many of these chronic complications.

Asunto(s)

Infecciones por VIH/complicaciones , Complejo SIDA Demencia/diagnóstico , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/etiología , Enteropatía por VIH/diagnóstico , Humanos , Enfermedades Metabólicas/diagnóstico , Enfermedades Metabólicas/etiología

RESUMEN

Enteropathy in HIV infection is not eliminated with combination antiretroviral therapy and is possibly linked to microbial translocation. We used a rapidly progressing SIV/pigtailed macaque model of HIV to examine enteropathy and microbial translocation. Histologic evidence of intestinal disease was observed in only half of infected macaques during late-stage infection (LSI). Combination antiretroviral therapy initiated during acute infection prevented intestinal disease. In the ileum and colon, enteropathy was associated with increased caspase-3 staining, decreased CD3+ T cells, and increased SIV-infected cells. CD3+ T cells were preserved in LSI animals without intestinal disease, and levels of CD3 staining in all LSI animals strongly correlated with the number of infected cells in the intestine and plasma viral load. Unexpectedly, there was little evidence of microbial translocation as measured by soluble CD14, soluble CD163, lipopolysaccharide binding protein, and microbial 16s ribosomal DNA. Loss of epithelial integrity indicated by loss of the tight junction protein claudin-3 was not observed during acute infection despite significantly fewer T cells. Claudin-3 was reduced in LSI animals with severe intestinal disease but did not correlate with increased microbial translocation. LSI animals that did not develop intestinal disease had increased T-cell intracytoplasmic antigen 1-positive cytotoxic T lymphocytes, suggesting a robust adaptive cytotoxic T-lymphocyte response may, in part, confer resilience to SIV-induced intestinal damage.

Asunto(s)

Síndrome de Inmunodeficiencia Adquirida/patología , Enteropatía por VIH/patología , Síndrome de Inmunodeficiencia Adquirida del Simio/patología , Enfermedad Aguda , Animales , Antígenos CD/metabolismo , Terapia Antirretroviral Altamente Activa , Caspasa 3/metabolismo , Claudina-3/metabolismo , Colon/enzimología , Colon/patología , Modelos Animales de Enfermedad , Quimioterapia Combinada , Células Epiteliales/metabolismo , Enteropatía por VIH/sangre , Enteropatía por VIH/virología , Íleon/enzimología , Íleon/patología , Inmunohistoquímica , Intestinos/patología , Macaca mulatta , Proteínas de Unión a Poli(A)/metabolismo , Síndrome de Inmunodeficiencia Adquirida del Simio/sangre , Síndrome de Inmunodeficiencia Adquirida del Simio/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida del Simio/virología , Virus de la Inmunodeficiencia de los Simios/fisiología , Linfocitos T/metabolismo , Carga Viral

RESUMEN

Introducción: el tracto gastrointestinal es un sitio frecuentemente afectado por el VIH; sin embargo, en la práctica clínica algunos hallazgos normales en la endoscopia pueden no serlo, lo cual conlleva a estos pacientes a no recibir tratamiento oportuno para patologías gastrointestinales. Métodos: estudio observacional descriptivo en pacientes con VIH que consultaron por síntomas digestivos y que requirieron endoscopia y/o colonoscopia durante el año 2014 en el Hospital Universitario de Santander. Se tomaron datos sociodemográficos, clínicos y paraclínicos. Se realizaron 41 endoscopias altas y 29 colonoscopias en 54 pacientes. A todo estudio se le practicó biopsia. Resultados: la edad promedio fue de 39 años, la sintomatología digestiva con mayor reporte fue la diarrea y las lesiones orales; 87% tenían conteo menor a 200 CD4, solo 24% reciben actualmente TARAE. Los diagnósticos más frecuentes por anatomía patológica diferentes a normalidad fueron: Candidiasis (17%) en esófago, gastritis crónica moderada (26,7%) en estómago y colitis crónica inespecífica moderada tanto en colon izquierdo (44,8%) como en colon derecho (51,7%). Conclusiones: los hallazgos endoscópicos y patológicos concuerdan con la frecuencia de presentaciones reportadas en la literatura, aunque no se encontraron neoplasias ni agentes infecciosos como micobacterias. Los oportunistas más frecuentes fueron la cándida y el citomegalovirus. Al confrontar el diagnóstico de normalidad entre el endoscopista y la anatomía patológica, solamente en esófago había una concordancia aceptable, a diferencia del estómago y el colon, donde la disparidad es evidente. Por lo anterior, en pacientes con VIH/sida que requieran endoscopia sería importante siempre considerar la toma biopsias de manera protocolizada.

---

Introduction: Although the gastrointestinal tract is frequently affected by HIV, in clinical practice abnormalities related to HIV often appear to be normal when seen through an endoscope. The consequence is that these patients do not receive timely treatment for gastrointestinal diseases. Methods: This is an observational study of HIV patients who came to the hospital of the Universidad Industrial de Santander because of digestive symptoms that required either endoscopy or colonoscopy, or both ,during 2014. Socio-demographic, clinical and laboratory data were collected. A total of 41 upper endoscopies and 29 colonoscopies were performed in 54 patients. Biopsies were taken and analyzed in all cases. Results: The mean patient age was 39 years old, the most frequent digestive symptoms were diarrhea and oral lesions, 87% of these patients had CD4 counts below 200, and only 24% currently receive HAART. The most frequent diagnoses were: esophageal candidiasis (17%), moderate chronic gastritis in the stomach (26.7%), and moderate chronic nonspecific colitis in the left colon (44.8%) and in the right colon (51.7%). Conclusions: Endoscopic and pathological findings are consistent with the frequencies of presentations of gastrointestinal pathologies reported in the literature except that no tumors or infectious agents such as mycobacteria were found. The most common opportunistic infections were Candida and Cytomegalovirus. Diagnostic agreement between the endoscopist and pathologist varied. There was had only fair agreement for the esophagus, but there were large disparities for the stomach and colon. Consequently, when HIV/AIDS patients require endoscopy, it is important that the protocol call for biopsy samples and analysis.

Asunto(s)

Humanos , Masculino , Femenino , Adulto , Anomalías del Sistema Digestivo , Endoscopía , Enteropatía por VIH , Infecciones por VIH

RESUMEN

Twenty years ago, there was profound, international interest in developing oral human, bovine, or chicken egg-derived immunoglobulin (Ig) for the prevention and nutritional treatment of childhood malnutrition and gastrointestinal disease, including acute diarrhea and necrotizing enterocolitis. Although such Ig products were shown to be effective, with both nutritional and antidiarrheal benefits, interest waned because of their cost and because of the perceived risk of bovine serum encephalitis (BSE). BSE is no longer considered a barrier to use of oral Ig, because the WHO has declared the United States to be BSE-free since the early 2000s. Low-cost bovine-derived products with high Ig content have been developed and are regulated as medical foods. These new products, called serum bovine Igs (SBIs), facilitate the management of chronic or severe gastrointestinal disturbances in both children and adults and are regulated by the US Food and Drug Administration. Well-established applications for use of SBIs include human immunodeficiency virus (HIV)-associated enteropathy and diarrhea-predominant irritable bowel syndrome. However, SBIs and other similar products could potentially become important components of the treatment regimen for other conditions, such as inflammatory bowel disease, by aiding in disease control without immunosuppressive side effects. In addition, SBIs may be helpful in conditions associated with the depletion of circulating and luminal Igs and could potentially play an important role in critical care nutrition. The rationale for their use is to facilitate intraluminal microbial antibody coating, an essential process in immune recognition in the gut which is disturbed in these conditions, thereby leading to intestinal inflammation. Thus, oral Ig may emerge as an important "add-on" therapy for a variety of gastrointestinal and nutritional problems during the next decade.

Asunto(s)

Nutrición Enteral , Enfermedades Gastrointestinales/tratamiento farmacológico , Inmunoglobulinas/uso terapéutico , Intestinos/efectos de los fármacos , Desnutrición/prevención & control , Adulto , Animales , Bovinos , Niño , Cuidados Críticos , Diarrea/tratamiento farmacológico , Enteropatía por VIH/tratamiento farmacológico , Humanos , Inmunoglobulinas/administración & dosificación , Inmunoglobulinas/farmacología , Inflamación/tratamiento farmacológico , Intestinos/inmunología , Intestinos/patología , Desnutrición/terapia , Pediatría

RESUMEN

Human immunodeficiency virus (HIV) infection is associated with increased intestinal translocation of microbial products and enteropathy as well as alterations in gut bacterial communities. However, whether the enteric virome contributes to this infection and resulting immunodeficiency remains unknown. We characterized the enteric virome and bacterial microbiome in a cohort of Ugandan patients, including HIV-uninfected or HIV-infected subjects and those either treated with anti-retroviral therapy (ART) or untreated. Low peripheral CD4 T cell counts were associated with an expansion of enteric adenovirus sequences and this increase was independent of ART treatment. Additionally, the enteric bacterial microbiome of patients with lower CD4 T counts exhibited reduced phylogenetic diversity and richness with specific bacteria showing differential abundance, including increases in Enterobacteriaceae, which have been associated with inflammation. Thus, immunodeficiency in progressive HIV infection is associated with alterations in the enteric virome and bacterial microbiome, which may contribute to AIDS-associated enteropathy and disease progression.

Asunto(s)

Síndrome de Inmunodeficiencia Adquirida/microbiología , Síndrome de Inmunodeficiencia Adquirida/virología , Bacterias/aislamiento & purificación , Microbioma Gastrointestinal , Microbiota , Virus/aislamiento & purificación , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Síndrome de Inmunodeficiencia Adquirida/inmunología , Antirretrovirales/uso terapéutico , Bacterias/clasificación , Bacterias/genética , Linfocitos T CD4-Positivos/inmunología , Variación Genética , Enteropatía por VIH/etiología , Voluntarios Sanos , Humanos , Filogenia , Uganda , Virus/clasificación , Virus/genética

RESUMEN

Over half of patients with human immunodeficiency virus (HIV) experience diarrhea that contributes negatively to quality of life and adherence to antiretroviral therapy (ART). Opportunistic infectious agents that cause diarrhea in patients with HIV span the array of protozoa, fungi, viruses, and bacteria. With global use of ART, the incidence of diarrhea because of opportunistic infections has decreased; however, the incidence of noninfectious diarrhea has increased. The etiology of noninfectious diarrhea in patients with HIV is multifactorial and includes ART-associated diarrhea and gastrointestinal damage related to HIV infection (i.e., HIV enteropathy). A basic algorithm for the diagnosis of diarrhea in patients with HIV includes physical examination, a review of medical history, assessment of HIV viral load and CD4+ T cell count, stool microbiologic assessment, and endoscopic evaluation, if needed. For patients with negative diagnostic results, the diagnosis of noninfectious diarrhea may be considered. Pharmacologic options for the treatment of noninfectious diarrhea are primarily supportive; however, the use of many unapproved agents is based on unstudied and anecdotal information. In addition, these agents can be associated with treatment-limiting adverse events (AEs), such as drug-drug interactions with ART regimens, abuse liability, and additional gastrointestinal AEs. Currently, crofelemer, an antisecretory agent, is the only therapy approved in the USA for the symptomatic relief of noninfectious diarrhea in patients with HIV on ART.

Asunto(s)

Antirretrovirales/efectos adversos , Diarrea/inducido químicamente , Diarrea/virología , Enteropatía por VIH , Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Infecciones Oportunistas Relacionadas con el SIDA/fisiopatología , Infecciones Oportunistas Relacionadas con el SIDA/terapia , Algoritmos , Antirretrovirales/uso terapéutico , Antidiarreicos/uso terapéutico , Enteropatía por VIH/tratamiento farmacológico , Enteropatía por VIH/fisiopatología , Humanos , Proantocianidinas/uso terapéutico

RESUMEN

A variety of human disease conditions are associated with chronic intestinal disorders or enteropathies that are characterized by intestinal inflammation, increased gut permeability, and reduced capacity to absorb nutrients. Such disruptions in the homeostasis of the gastrointestinal (GI) tract can lead to symptoms of abdominal pain and discomfort, bloating, abnormal bowel function, and malabsorption of nutrients. While significant advances have been made in understanding the factors that influence the complex and fragile balance between the gut microbiota, intestinal epithelial cell integrity, and the underlying immune system, effective therapies for restoring intestinal balance during enteropathy are still not available. Numerous studies have demonstrated the ability of oral immunoglobulins to improve weight gain, support gut barrier function, and reduce the severity of enteropathy in animals. More recently, studies in humans provide evidence that serum-derived bovine immunoglobulin/protein isolate is safe and improves nutritional status and GI symptoms in patients with enteropathy associated with irritable bowel syndrome or infection with the human immunodeficiency virus. This review summarizes studies showing the impact of enteropathy on nutritional status and how specially formulated bovine immunoglobulins may help restore intestinal homeostasis and nutritional status in patients with specific enteropathies. Such protein preparations may provide distinct nutritional support required for the dietary management of patients who, because of therapeutic or chronic medical needs, have limited or impaired capacity to digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or other special medically determined nutrient requirements that cannot be satisfied by changes to the normal diet alone.

Asunto(s)

Enfermedades Intestinales/dietoterapia , Duodeno/inmunología , Duodeno/microbiología , Enteropatía por VIH/dietoterapia , Humanos , Inmunoglobulinas/administración & dosificación , Enfermedades Intestinales/inmunología , Intestinos/inmunología , Intestinos/microbiología , Síndrome del Colon Irritable/dietoterapia , Estado Nutricional , Seroglobulinas/administración & dosificación

RESUMEN

PURPOSE OF REVIEW: Despite decreases in morbidity and mortality as a result of antiretroviral therapy, gastrointestinal dysfunction remains common in HIV infection. Treated patients are at risk for complications of 'premature' aging, such as cardiovascular disease, osteopenia, neurocognitive decline, malignancies, and frailty. This review summarizes recent observations in this field. RECENT FINDINGS: Mucosal CD4 lymphocytes, especially Th17 cells, are depleted in acute HIV and simian immune deficiency virus (SIV) infections, although other cell types also are affected. Reconstitution during therapy often is incomplete, especially in mucosa. Mucosal barrier function is affected by both HIV infection and aging and includes paracellular transport via tight junctions and uptake through areas of apoptosis; other factors may affect systemic antigen exposure. The resultant microbial translocation is associated with systemic immune activation in HIV and SIV infections. There is evidence of immune activation and microbial translocation in the elderly. The immune phenotypes of immunosenescence in HIV infection and aging appear similar. There are several targets for intervention; blockage of residual mucosal virus replication, preventing antigen uptake, modulating the microbiome, improving T cell recovery, combining therapies aimed at mucosal integrity, augmenting mucosal immunity, and managing traditional risk factors for premature aging in the general population. SUMMARY: Aging may interact with HIV enteropathy to enhance microbial translocation and immune activation.

Asunto(s)

Envejecimiento , Enteropatía por VIH/epidemiología , Infecciones por VIH/epidemiología , Traslocación Bacteriana , Comorbilidad , Infecciones por VIH/tratamiento farmacológico , Humanos , Inmunidad Mucosa , Mucosa Intestinal/inmunología

RESUMEN

The widespread access to antiretroviral treatment during the past decades has transformed HIV infection from a lethal disease to a chronic condition, in which the relative burden of non-AIDS-related chronic disorders such as cardiovascular disease, malignancy, renal, liver, and bone disease has increased. The adjusted relative risk for myocardial infarction is reported to be around 2-fold compared to that of the general population, which over time is likely to translate into increased absolute risk in an aging population. Thus, delineating potentially HIV-specific pathogenetic mechanisms is crucial in order to tailor novel strategies for prophylaxis and treatment. This review will focus on advances in the field that possibly link HIV-induced alterations of the gut mucosa and consequent microbial translocation to cardiometabolic risk factors in HIV infection. Recent work suggests that markers of microbial translocation are closely associated with several cardiovascular risk factors such as dyslipidemia, insulin resistance, hypertension, coagulation abnormalities, endothelial dysfunction, and carotid atherosclerosis. Future studies should investigate whether associations between microbial translocation and cardiovascular risk factors will translate into increased risk of acute events, and whether strategies to target gut microbiota and microbial translocation might reduce such a risk.

Asunto(s)

Traslocación Bacteriana , Enfermedades Cardiovasculares/epidemiología , Enteropatía por VIH/complicaciones , Humanos , Factores de Riesgo

RESUMEN

BACKGROUND: Hepatitis E virus (HEV) infection causes major epidemics of infectious hepatitis, with high mortality rates in pregnant women. Recent reports indicate that HEV coinfections with human immunodeficiency virus (HIV) may have a more protracted course. However, the impact of HEV infections in communities heavily affected by HIV remains poorly studied. We set out to examine age-related seroprevalence in a community where we have previously carried out studies on environmental enteropathy. METHODS: Blood samples from 194 children and 106 adults were examined for immunoglobulin G and immunoglobulin M antibodies for HEV. HEV data were correlated with HIV status and morphometric analysis of small intestinal biopsies. RESULTS: Seroprevalence rose throughout childhood, from 8% in children aged 1-4 years, to 36% in children aged 10-14 years. In adults, the overall prevalence was 42%, with 28% in HIV-seronegative adults and 71% in HIV-seropositive adults (odds ratio, 6.2; 95% confidence interval, 2.2-18; P = .0001). In adults, villous height and crypt depth measurements showed that HEV seropositivity was associated with worse enteropathy (P = .05 and P = .005, respectively). CONCLUSIONS: HEV infection is common in Zambia. In adults it is strongly associated with HIV status, and also with environmental enteropathy.

Asunto(s)

Enteropatía por VIH/virología , Infecciones por VIH/virología , Hepatitis E/epidemiología , Hepatitis E/virología , Adolescente , Adulto , Niño , Preescolar , Coinfección/sangre , Coinfección/virología , Femenino , Enteropatía por VIH/sangre , Infecciones por VIH/sangre , Anticuerpos Antihepatitis/sangre , Hepatitis E/sangre , Virus de la Hepatitis E , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Lactante , Masculino , Estudios Seroepidemiológicos , Población Urbana , Zambia/epidemiología

RESUMEN

OBJECTIVE: To analyse the structural and kinetic response of small intestinal crypt epithelial cells including stem cells to highly active antiretroviral therapy (HAART). DESIGN: Crypt size and proliferative activity of transit and stem cells in jejunal mucosa were quantified using morphometric techniques. METHODS: Crypt length was measured by counting the number of enterocytes along one side of a number of crypts in each biopsy specimen and the mean crypt length was calculated. Proliferating crypt cells were identified with MIB-1 monoclonal antibody, and the percentage of crypt cells in proliferation was calculated at each cell position along the length of the crypt (proliferation index). Data were obtained from 9 HIV-positive test patients co-infected with microsporidia, 34 HIV-positive patients receiving HAART and 13 control cases. RESULTS: Crypt length was significantly greater in test patients than in controls, but crypt length in patients receiving HAART was normal. The proliferation index was greater in test subjects than in controls in stem and transit cell compartments, and was decreased in patients treated with HAART only in the stem cell region of the crypt. CONCLUSIONS: Villous atrophy in HIV enteropathy is attributed to crypt hypertrophy and encroachment of crypt cells onto villi. HAART restores normal crypt structure by inhibition of HIV-driven stem cell hyperproliferation at the crypt bases.

Asunto(s)

Terapia Antirretroviral Altamente Activa , Proliferación Celular/efectos de los fármacos , Enteropatía por VIH/patología , Mucosa Intestinal/patología , Células Madre/efectos de los fármacos , Enteropatía por VIH/tratamiento farmacológico , Humanos , Hipertrofia/patología , Mucosa Intestinal/efectos de los fármacos , Yeyuno/efectos de los fármacos , Yeyuno/patología , Índice Mitótico , Células Madre/patología

RESUMEN

Crofelemer is the first US FDA-approved drug for symptomatic relief in HIV-infected persons on antiretroviral therapy (ART) who have non-infectious diarrhea. With the availability of ART, there is increased survival and decrease in gastrointestinal opportunistic infections. However, diarrhea secondary to ART and HIV enteropathy is common in HIV-infected persons. Crofelemer is manufactured from the red latex sap of the Croton lechleri tree in South America. It has a unique mechanism leading to inhibition of chloride ion secretion by blocking chloride channels in the gastrointestinal lumen. This reduces efflux of sodium and water, which in turn reduces the frequency and consistency of diarrhea. Crofelemer is well tolerated due to minimal systemic absorption and has a good safety profile. The availability of crofelemer will likely have a positive impact on the quality of life in HIV-infected persons and also increase compliance to ART.

Asunto(s)

Fármacos Anti-VIH/efectos adversos , Canales de Cloruro/antagonistas & inhibidores , Diarrea/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Tracto Gastrointestinal/efectos de los fármacos , Enteropatía por VIH/tratamiento farmacológico , Infecciones por VIH/tratamiento farmacológico , Proantocianidinas/uso terapéutico , Animales , Canales de Cloruro/metabolismo , Diarrea/diagnóstico , Diarrea/etiología , Diarrea/metabolismo , Fármacos Gastrointestinales/efectos adversos , Tracto Gastrointestinal/metabolismo , Enteropatía por VIH/diagnóstico , Enteropatía por VIH/etiología , Enteropatía por VIH/metabolismo , Infecciones por VIH/complicaciones , Infecciones por VIH/diagnóstico , Humanos , Cumplimiento de la Medicación , Proantocianidinas/efectos adversos , Calidad de Vida , Factores de Riesgo , Resultado del Tratamiento

RESUMEN

OBJECTIVES: To examine the impact of serum-derived bovine immunoglobulin, an oral medical food known to neutralize bacterial antigen and reduce intestinal inflammation, on restoration of mucosal immunity and gastrointestinal function in individuals with HIV enteropathy. DESIGN: Open-label trial with intensive 8-week phase of bovine serum immunoglobulin (SBI) 2.5 g twice daily with a 4-week washout period and an optional 9-month extension study. METHODS: HIV enteropathy was defined as chronic gastrointestinal symptoms including frequent loose or watery stools despite no identifiable, reversible cause. Upper endoscopy for tissue immunofluorescent antibody assay and disaccharide gut permeability/absorption studies were performed before and after 8 weeks of SBI to test mucosal immunity and gastrointestinal function. Blood was collected for markers of microbial translocation, inflammation, and collagen kinetics. A validated gastrointestinal questionnaire assessed changes in symptoms. RESULTS: All eight participants experienced profound improvement in symptoms with reduced bowel movements/day (P = 0.008) and improvements in stool consistency (P = 0.008). Gut permeability was normal before and after the intervention, but D-xylose absorption increased in seven of eight participants. Mucosal CD4 lymphocyte densities increased by a median of 139.5 cells/mm2 from 213 to 322 cells/mm2 (P = 0.016). Intestinal-fatty acid binding protein (I-FABP), a marker of enterocyte damage, initially rose in seven of eight participants after 8 weeks (P = 0.039), and then fell below baseline in four of five who continued receiving SBI (P = 0.12). Baseline serum I-FABP levels were negatively correlated with subsequent rise in mucosal CD4 lymphocyte densities (r = -0.74, P = 0.046). CONCLUSION: SBI significantly increases intestinal mucosal CD4 lymphocyte counts, improves duodenal function, and showed evidence of promoting intestinal repair in the setting of HIV enteropathy.

Asunto(s)

Adsorción , Dieta/métodos , Duodeno/inmunología , Enteropatía por VIH/terapia , Inmunidad Mucosa , Inmunoglobulinas/administración & dosificación , Seroglobulinas/administración & dosificación , Administración Oral , Adulto , Animales , Recuento de Linfocito CD4 , Bovinos , Duodeno/patología , Duodeno/fisiopatología , Enteropatía por VIH/inmunología , Humanos , Inmunoglobulinas/aislamiento & purificación , Masculino , Proyectos Piloto , Seroglobulinas/aislamiento & purificación , Resultado del Tratamiento

RESUMEN

BACKGROUND: HIV-infection results in damage and dysfunction of the gastrointestinal system. HIV enteropathy includes pronounced CD4+ T-cell loss, increased intestinal permeability, and microbial translocation that promotes systemic immune activation, which is implicated in disease progression. A synbiotic is the combination of probiotics and prebiotics that could improve gut barrier function. Our study goal was to determine whether the use of a synbiotic, probiotics or a prebiotic can recover immunological parameters in HIV-infected subjects through of a reduction of microbial translocation and pro-inflammatory cytokine production. METHODS: A randomized, double-blind controlled study was performed; twenty Antiretroviral treatment-naïve HIV-infected subjects were subgrouped and assigned to receive a synbiotic, probiotics, a prebiotic, or a placebo throughout 16 weeks. RESULTS: We had no reports of serious adverse-events. From baseline to week 16, the synbiotic group showed a reduction in bacterial DNA concentrations in plasma (p = 0.048). Moreover, the probiotic and synbiotic groups demonstrated a decrease in total bacterial load in feces (p = 0.05). The probiotic group exhibited a significant increment of beneficial bacteria load (such as Bifidobacterium; p = 0.05) and a decrease in harmful bacteria load (such as Clostridium; p = 0.063). In the synbiotic group, the CD4+ T-cells count increased (median: +102 cells/µL; p = 0.05) and the level of Interleukin 6 cytokine decreased significantly (p = 0.016). CONCLUSIONS: Our study showed a significant increase in CD4+ T lymphocyte levels in the synbiotic group, which could delay the initiation of antiretroviral therapy and decrease costs in countries with limited resources.

Asunto(s)

Antiinflamatorios no Esteroideos/uso terapéutico , Traslocación Bacteriana , Enteropatía por VIH/dietoterapia , Mucosa Intestinal/microbiología , Prebióticos , Probióticos , Adulto , Antiinflamatorios no Esteroideos/efectos adversos , Bifidobacterium/clasificación , Bifidobacterium/crecimiento & desarrollo , Bifidobacterium/inmunología , Bifidobacterium/aislamiento & purificación , Recuento de Linfocito CD4 , Citocinas/sangre , Citocinas/metabolismo , ADN Bacteriano/sangre , Progresión de la Enfermedad , Método Doble Ciego , Heces/microbiología , Femenino , Enteropatía por VIH/inmunología , Enteropatía por VIH/microbiología , Enteropatía por VIH/fisiopatología , Humanos , Mucosa Intestinal/inmunología , Mucosa Intestinal/fisiopatología , Lacticaseibacillus rhamnosus/clasificación , Lacticaseibacillus rhamnosus/crecimiento & desarrollo , Lacticaseibacillus rhamnosus/inmunología , Lacticaseibacillus rhamnosus/aislamiento & purificación , Masculino , México , Proyectos Piloto , Prebióticos/efectos adversos , Probióticos/efectos adversos , Probióticos/aislamiento & purificación , Calidad de Vida , Adulto Joven

RESUMEN

No disponible

Asunto(s)

Humanos , Masculino , Anciano , Enfermedades de la Piel/complicaciones , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/mortalidad , Enfermedades de la Piel/prevención & control , Enfermedades de la Piel/terapia , Infecciones por VIH , VIH/inmunología , Enteropatía por VIH , Linfocitos T CD8-positivos , Terapia de Inmunosupresión , Linfoma Cutáneo de Células T , Informes de Casos , Síndrome Hipereosinofílico , Dermatitis Atópica , Dermatitis por Contacto

RESUMEN

Diarrhea is a common problem in patients with immunocompromising conditions. The etiologic spectrum differs from patients with diarrhea who have a normal immune system. This article reviews the most important causes of diarrhea in immunocompromised patients, ranging from infectious causes to noninfectious causes of diarrhea in the setting of HIV infection as a model for other conditions of immunosuppression. It also deals with diarrhea in specific situations, eg, after hematopoietic stem cell or solid organ transplantation, diarrhea induced by immunosuppressive drugs, and diarrhea in congenital immunodeficiency syndromes.

Asunto(s)

Diarrea/etiología , Huésped Inmunocomprometido , Antiinfecciosos/uso terapéutico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Enterocolitis Neutropénica/complicaciones , Enfermedad Injerto contra Huésped/complicaciones , Enteropatía por VIH/complicaciones , Infecciones por VIH/complicaciones , Histoplasmosis/complicaciones , Histoplasmosis/diagnóstico , Histoplasmosis/tratamiento farmacológico , Humanos , Síndromes de Inmunodeficiencia/complicaciones , Parasitosis Intestinales/complicaciones , Parasitosis Intestinales/tratamiento farmacológico , Intestinos/microbiología , Intestinos/parasitología , Intestinos/virología , Microsporidiosis/complicaciones , Microsporidiosis/diagnóstico , Microsporidiosis/tratamiento farmacológico , Infecciones Oportunistas/complicaciones , Trasplante de Órganos/efectos adversos , Trasplante de Células Madre/efectos adversos , Virosis/complicaciones , Virosis/tratamiento farmacológico

RESUMEN

A spectrum of enteropathies, characterized by small intestinal inflammation, reduced absorptive capacity, and increased intestinal permeability, commonly affect people in developing countries. This subclinical intestinal pathology facilitates microbial translocation across the compromised intestinal barrier, leading to chronic systemic inflammation that may adversely impact health. Environmental enteropathy (EE), ubiquitous among people living in unhygienic conditions, likely mediates two interlinked public health problems of childhood, stunting and anemia, and underlies poor oral vaccine efficacy in developing countries. Human immunodeficiency virus (HIV) enteropathy, which frequently overlaps with EE, may contribute to immune activation and modulate HIV disease progression. The interacting effects of infection and enteropathy drive a vicious cycle that can propagate severe acute malnutrition, which underlies almost half of under-5-y deaths. Enteropathies are therefore highly prevalent, interacting causes of morbidity and mortality in developing countries. Interventions to prevent or ameliorate enteropathies have potential to improve the health of millions of people in developing countries.

Asunto(s)

Países en Desarrollo , Enteropatía por VIH/epidemiología , Enfermedades Intestinales/epidemiología , Enteropatía por VIH/diagnóstico , Enteropatía por VIH/terapia , Humanos , Enfermedades Intestinales/diagnóstico , Enfermedades Intestinales/terapia , Morbilidad , Salud Pública

RESUMEN

INTRODUCTION: Studies strongly indicate Dientamoeba fragilis as one of the causes of diarrhea in human immunodeficiency virus (HIV) patients. METHODS: The objective of the present study was to evaluate the prevalence of D. fragilis associated with the causes of diarrhea in 82 HIV/ AIDS patients hospitalized at the Instituto de Infectologia Emílio Ribas from September 2006 to November 2008. RESULTS: In total, 105 samples were collected from 82 patients. Unprotected sex was the most frequent cause of HIV infection (46.3%), followed by the use of injectable or non-injectable drugs (14.6%). Patients presented with viral loads of 49-750,000 copies/ mL (average: 73,849 ± 124,850 copies/mL) and CD4 counts ranging of 2-1,306 cells/mm³ (average: 159 ± 250 cells/mm³). On an average, the odds of obtaining a positive result by using the other techniques (Hoffman, Pons and Janer or Lutz; Ritchie) were 2.7 times higher than the chance of obtaining a positive result by using the simplified iron hematoxylin method. Significant differences were found between the methods (p = 0.003). CONCLUSIONS: The other techniques can detect a significantly greater amount of parasites than the simplified iron hematoxylin method, especially with respect to Isospora belli, Cryptosporidium sp., Schistosoma mansoni, and Strongyloides stercoralis, which were not detected using hematoxylin. Endolimax nana and D. fragilis were detected more frequently on using hematoxylin, and the only parasite not found by the other methods was D. fragilis.

Asunto(s)

Diarrea/parasitología , Dientamoeba/aislamiento & purificación , Dientamebiasis/diagnóstico , Heces/parasitología , Enteropatía por VIH/parasitología , Adulto , Femenino , Enteropatía por VIH/diagnóstico , Hematoxilina , Humanos , Masculino , Prevalencia , Coloración y Etiquetado